Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model

Chemotherapy

Volumn 58, Issue 2, 2012, Pages 159-164

  Szilagyi J ^a   Foldi R ^a   Gesztelyi, R ^a   Bayegan, S ^a   Kardos, G ^a   Juhasz B ^a   Majoros, L ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Fungal tissue burden; In vivo susceptibility; Psilosis group

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CASPOFUNGIN; FLUCONAZOLE; MYCOSIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; EXPERIMENTAL ANIMAL; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE CANDIDIASIS; KIDNEY INFECTION; KRUSKAL WALLIS TEST; MOUSE; NEUTROPENIA; NONHUMAN; PATHOGEN LOAD; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; DISEASE MODELS, ANIMAL; ECHINOCANDINS; FEMALE; FLUCONAZOLE; IMMUNOCOMPROMISED HOST; KIDNEY; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA;

EID: 84861338031     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000337088     Document Type: Article

References (25)

1. Tavanti A, Davidson AD, Gow NAR, Maiden MCJ, Odds FC: Candida orthopsilosis and Candida metapsilosis spp. nov., to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-292.
2. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ: Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis, in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 2008; 46: 2659-2664.
3. Gácser A, Schäfer W, Nosanchuk JS, Salomon S, Nosanchuk JD: Virulence of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis in reconstituted human tissue models. Fungal Genet Biol 2007; 44: 1336-1341.
4. Orsi CF, Colombari B, Blasi E: Candida metapsilosis as the least virulent member of the 'C. parapsilosis' complex. Med Mycol 2010; 48: 1024-1033.
5. van Asbeck E, Clemons KV, Martinez M, Tong AJ, Stevens DA: Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis 2008; 62: 106-109.
6. Gómez-López A, Alastruey-Izquierdo A, Rodríguez D, Almirante B, Pahissa A, Rodríguez-Tudela JL, Cuenca-Estrella M, the Barcelona Candidemia Project Study Group: Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008; 52: 1506-1509.
7. Varga I, Sóczó G, Kardos G, Borbély A, SzabóZ, Kemény-Beke A, Majoros L: Comparison of killing activity of caspofungin against Candida parapsilosis, C. orthopsilosis and C. metapsilosis. J Antimicrob Chemother 2008; 62: 1466-1468.
8. Szabó Z, Szilágyi J, Tavanti A, Kardos G, Rozgonyi F, Bayegan S, Majoros L: In vitro efficacy of 5 antifungal agents against Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis as determined by time-kill methodology. Diagn Microbiol Infect Dis 2009; 64: 283-288.
9. Cantón E, Espinel-Ingroff A, Pemán J, del Castillo L: In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother 2010; 54: 2194-2197.
10. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS: A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305-2312.
11. Carrillo-Muñoz AJ, Quindós G, del Valle O, Santos P, Giusiano G, Ezkurra PA, Estivill MD, Casals JB: Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets. Chemotherapy 2008; 54: 38-42.
12. Swoboda S, Lichtenstern C, Ober MC, Taylor LA, Störzinger D, Michel A, Brobeil A, Mieth M, Hofer S, Sonntag HG, Hoppe-Tichy T, Weigand MA: Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy 2009; 55: 418-424.
13. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, ed 3. CLSI document M27-A3. Wayne, Clinical and Laboratory Standards Institute, 2008.
14. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D, CLSI Subcommittee for Antifungal Susceptibility Testing: Wildtype MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-195.
15. Kunz AN, Brook I: Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections. Chemotherapy 2010; 56: 492-500.
16. Mohammadtaheri Z, Pourpaki M, Mohammadi F, Namdar R: Surveillance of antimicrobial susceptibility among bacterial isolates from intensive care unit patients of a tertiary-care university hospital in Iran: 2006-2009. Chemotherapy 2010; 56: 478-484.
17. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, the CLSI Subcommittee for Antifungal Testing: Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-176.
18. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Fil ler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America: Clinical Practice Guidelines for the management of candidiasis: update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
19. Hope WW, Drusano GL: Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect 2009; 15: 602-612.
20. Louie A, Banerjee P, Drusano GL, Shayegani M, Miller MH: Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother 1999; 43: 2841-2847.
21. Flattery AM, Hickey E, Gill CJ, Powles MA, Misura AS, Galgoci AM, Ellis JD, Zhang R, Sandhu P, Ronan J, Abruzzo GK: Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. Antimicrob Agents Chemother 2011; 55: 3491-3497.
22. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA: Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-745.
23. Migoya EM, Mistry GC, Stone JA, Comisar W, Sun P, Norcross A, Bi S, Winchell GA, Ghosh K, Uemera N, Deutsch PJ, Wagner JA: Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol 2011; 51: 202-211.
24. Barchiesi F, Spreghini E, Tomassetti S, Della Vittoria A, Arzeni D, Manso E, Scalise G: Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006; 50: 2719-2727.
25. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, Strohmaier KM, Tucker KA, Taylor AF, Kartsonis NA, Caspofungin High-Dose Study Group: A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-1684.